CTSH three-lens brief
Evidence-based stock research on CTSH. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 26.6pp over 30 days. · Trading at 1% of its 52-week range — deep in the lower band.
- Trading at 1% of its 52-week range — deep in the lower band.
- RSI at 26 — technically oversold.
- Underperforming SPY by 26.6pp over 30 days.
- P/E of 11.4 — trading at a value multiple.
- Analyst mean target $75.48 — 44% above current (26 analysts).
CTSH closed at $52.54 (+0.21%) as of 2026-05-04. Market cap: $24.85B. P/E (trailing) 11.4. Positives: p/E of 11.4 — trading at a value multiple.; analyst mean target $75.48 — 44% above current (26 analysts).. Concerns: trading at 1% of its 52-week range — deep in the lower band.; rSI at 26 — technically oversold.. Last quarter: Revenue $5.41B, net income $662.00M, free cash flow $1.91B.
Why three lenses on CTSH, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CTSHacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CTSH" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CTSH brief"></iframe>